• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DICE Therapeutics, Amgen And Some Other Big Stocks Moving Higher On Tuesday

    10/11/22 10:39:04 AM ET
    $ALBO
    $AMGN
    $ARBE
    $BAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALBO alert in real time by email

    U.S. stocks traded mostly lower, with the Nasdaq dropping more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

    • DICE Therapeutics, Inc. (NASDAQ:DICE) shares surged 53.6% to $37.86 after the company announced topline data from its Phase 1 clinical trial of DC-806. Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group.
    • ForgeRock, Inc. (NYSE:FORG) gained 49.2% to $22.62 after the company announced it will be acquired by Thoma Bravo for $2.3 billion.
    • Bright Health Group, Inc. (NYSE:BHG) jumped 24.7% to $1.1350.
    • Albireo Pharma, Inc. (NASDAQ:ALBO) shares jumped 17.5% to $24.05 after the company announced topline results from the Phase 3 of Bylvay in Alagille syndrome showed highly statistically significant improvement in pruritus primary endpoint.
    • Amprius Technologies, Inc. (NASDAQ:AMPX) surged 17.3% to $8.79. Amprius Technologies was awarded $1 million Department of Energy funding grant for advanced battery manufacturing.
    • Braskem S.A. (NYSE:BAK) shares climbed 12.4% to $12.07 following a report suggesting Apollo has made a new offer for the company.
    • Annaly Capital Management, Inc. (NYSE:NLY) gained 8% to $16.33.
    • Douglas Elliman Inc. (NYSE:DOUG) surged 8% to $4.33.
    • Cementos Pacasmayo S.A.A. (NYSE:CPAC) shares rose 7.2% to $4.88.
    • Arbe Robotics Ltd. (NASDAQ:ARBE) gained 7% to $6.10.
    • Amgen Inc. (NASDAQ:AMGN) surged 6.7% to $247.62 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $257 to $279.
    • e.l.f. Beauty, Inc. (NYSE:ELF) rose 6.2% to $39.81. Piper Sandler upgraded e.l.f. Beauty from Neutral to Overweight and raised the price target from $35 to $46.
    Get the next $ALBO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBO
    $AMGN
    $ARBE
    $BAK

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    2/20/2026$185.00Equal Weight
    Barclays
    e.l.f. Beauty Inc.
    $ELF
    1/23/2026$110.00Buy
    Citigroup
    Amgen Inc.
    $AMGN
    1/20/2026$335.00Outperform → Mkt Perform
    Bernstein
    e.l.f. Beauty Inc.
    $ELF
    1/14/2026$110.00Buy
    Jefferies
    Amgen Inc.
    $AMGN
    1/7/2026$380.00Buy
    UBS
    Annaly Capital Management Inc.
    $NLY
    1/6/2026Neutral → Buy
    BTIG Research
    Amgen Inc.
    $AMGN
    12/5/2025Hold → Buy
    Erste Group
    Amgen Inc.
    $AMGN
    11/24/2025$318.00Hold
    Truist
    More analyst ratings

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Amgen with a new price target

    Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:35 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on e.l.f. Beauty with a new price target

    Citigroup initiated coverage of e.l.f. Beauty with a rating of Buy and set a new price target of $110.00

    1/23/26 8:18:55 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Amgen downgraded by Bernstein with a new price target

    Bernstein downgraded Amgen from Outperform to Mkt Perform and set a new price target of $335.00

    1/20/26 10:22:04 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farrell Matthew bought $464,814 worth of shares (5,000 units at $92.96), increasing direct ownership by 86% to 10,820 units (SEC Form 4)

    4 - e.l.f. Beauty, Inc. (0001600033) (Issuer)

    2/23/26 4:07:34 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Bartels Patrick J Jr bought $253,682 worth of shares (135,000 units at $1.88), increasing direct ownership by 229% to 193,975 units (SEC Form 4)

    4 - Douglas Elliman Inc. (0001878897) (Issuer)

    5/12/25 5:25:05 PM ET
    $DOUG
    Real Estate
    Finance

    Officer Liebowitz Michael bought $1,816,776 worth of shares (1,081,414 units at $1.68) (SEC Form 4)

    4 - Douglas Elliman Inc. (0001878897) (Issuer)

    11/19/24 8:45:05 AM ET
    $DOUG
    Real Estate
    Finance

    $ALBO
    $AMGN
    $ARBE
    $BAK
    SEC Filings

    View All

    SEC Form 6-K filed by Braskem SA ADR

    6-K - BRASKEM SA (0001071438) (Filer)

    2/27/26 5:31:00 PM ET
    $BAK
    Major Chemicals
    Industrials

    SEC Form 6-K filed by Arbe Robotics Ltd.

    6-K - Arbe Robotics Ltd. (0001861841) (Filer)

    2/26/26 12:06:02 PM ET
    $ARBE
    EDP Services
    Technology

    SEC Form 25-NSE filed by Amgen Inc.

    25-NSE - AMGEN INC (0000318154) (Subject)

    2/24/26 4:30:56 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

    The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

    3/3/26 5:31:00 PM ET
    $AMGN
    $IRON
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Arbe Announces Fourth Quarter and Full Year 2025 Financial Results

    TEL AVIV, Israel, Feb. 26, 2026 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ:ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced its financial results and provided an investor update for its fourth quarter and full year ending December 31, 2025. 2026 Strategy & Leadership UpdateAdvancing the company's market reach: Arbe is expanding its focus beyond automotive OEMs into related markets such as defense, robotaxi, robotruck, and off-road, and increasing its focus on the Chinese automotive market, where it has demonstrated traction and where it believes market timing is more immediate. These initiatives are expected to begin contributing to revenue in 2026, alongsid

    2/26/26 7:00:00 AM ET
    $ARBE
    EDP Services
    Technology

    Arbe Appoints Ram Machness as Chief Executive Officer; Kobi Marenko Appointed President

    With Arbe Advancing Into Its Next Strategic Phase, the Company Is Reinforcing Its Leadership Structure to Support Scaling, Deepen Customer Engagement, and Drive Long-Term Value CreationTEL AVIV, Israel, Feb. 26, 2026 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ:ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced that it is strengthening its leadership team as the Company advances into its next strategic phase. The Company has appointed Ram Machness, Arbe's Chief Business Officer, as Chief Executive Officer and appointed current CEO and co-founder Kobi Marenko as President. The official transition to the new roles will take place on April 1, 2026.

    2/26/26 6:55:00 AM ET
    $ARBE
    EDP Services
    Technology

    $ALBO
    $AMGN
    $ARBE
    $BAK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Operations Santos Esteban sold $20,772,595 worth of shares (54,792 units at $379.12) and exercised 54,792 shares at a strike of $169.19 (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    3/2/26 7:20:03 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Wolfe Serena was granted 83,106 shares and covered exercise/tax liability with 42,427 shares, increasing direct ownership by 24% to 213,760 units (SEC Form 4)

    4 - ANNALY CAPITAL MANAGEMENT INC (0001043219) (Issuer)

    2/27/26 4:21:11 PM ET
    $NLY
    Real Estate Investment Trusts
    Real Estate

    President and COO Campbell Steven Francis covered exercise/tax liability with 43,556 shares, sold $604,790 worth of shares (26,491 units at $22.83) and was granted 85,319 shares, increasing direct ownership by 7% to 219,763 units (SEC Form 4)

    4 - ANNALY CAPITAL MANAGEMENT INC (0001043219) (Issuer)

    2/27/26 4:21:23 PM ET
    $NLY
    Real Estate Investment Trusts
    Real Estate

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Financials

    Live finance-specific insights

    View All

    Cementos Pacasmayo S.A.A. Announces Consolidated Results for Fourth Quarter 2025

    Cementos Pacasmayo S.A.A. and subsidiaries (NYSE:CPAC, BVL: CPACASC1)) ("the Company" or "Pacasmayo") a leading cement company serving the Peruvian construction industry, announced today its consolidated results for the fourth quarter ("4Q25") and for the year ("2025") ended December 31, 2025. These results have been prepared in accordance with International Financial Reporting Standards ("IFRS") and are stated in Soles (S/). 4Q25 FINANCIAL AND OPERATIONAL HIGHLIGHTS: (All comparisons are to 4Q24, unless otherwise stated) On December 16, the Company announced that the Swiss company Holcim, had signed an agreement to purchase Inversiones Aspi S.A. of the Hochschild Group, which contro

    2/12/26 10:00:00 PM ET
    $CPAC
    Building Materials
    Industrials

    Annaly Capital Management, Inc. Announces Preferred Dividends

    In accordance with the terms of Annaly's 6.95% Series F Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock ("Series F Preferred Stock"), the Board has declared a Series F Preferred Stock cash dividend for the first quarter of 2026 of $0.557909 per share of Series F Preferred Stock, which reflects a rate of 8.92655%, equal to three-month CME Term SOFR (plus a spread adjustment of 0.26161%) on the Dividend Determination date plus a spread of 4.993%. In accordance with the terms of Annaly's 6.50% Series G Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock ("Series G Preferred Stock"), the Board has declared a Series G Preferred Stock cash dividend for the first quarter of

    2/11/26 4:15:00 PM ET
    $NLY
    Real Estate Investment Trusts
    Real Estate

    Arbe to Announce Fourth Quarter and Full Year 2025 Financial Results and Hold a Conference Call on February 26, 2026

    TEL AVIV, Israel, Feb. 10, 2026 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ:ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced that it will hold its fourth quarter and full year 2025 conference call on Thursday, February 26, 2026 at 8:30 a.m. Eastern Time. The company will issue its financial results before the US market opens that same day.     Conference Call and Webcast Details Speakers will include Kobi Marenko, Co-Founder and Chief Executive Officer and Karine Pinto-Flomenboim, Chief Financial Officer. The call will be webcast live and accessible from a link Arbe's Investor Relations website at: https://ir.arberobotics.com. The call may also be accessed v

    2/10/26 9:00:00 AM ET
    $ARBE
    EDP Services
    Technology

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Leadership Updates

    Live Leadership Updates

    View All

    Arbe Appoints Ram Machness as Chief Executive Officer; Kobi Marenko Appointed President

    With Arbe Advancing Into Its Next Strategic Phase, the Company Is Reinforcing Its Leadership Structure to Support Scaling, Deepen Customer Engagement, and Drive Long-Term Value CreationTEL AVIV, Israel, Feb. 26, 2026 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ:ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced that it is strengthening its leadership team as the Company advances into its next strategic phase. The Company has appointed Ram Machness, Arbe's Chief Business Officer, as Chief Executive Officer and appointed current CEO and co-founder Kobi Marenko as President. The official transition to the new roles will take place on April 1, 2026.

    2/26/26 6:55:00 AM ET
    $ARBE
    EDP Services
    Technology

    CEMENTOS PACASMAYO S.A.A. R.U.C. N° 20419387658 Notice of Annual Mandatory Shareholders' Meeting

    In accordance with the Company's bylaws and the General Corporations Law, the shareholders of CEMENTOS PACASMAYO S.A.A. are hereby convened to the Annual Mandatory Shareholders' Meeting, which will be held on first call, on March 24, 2026, at 9:00 a.m., at the corporate Company's registered office located at Calle la Colonia No. 150, Urb. El Vivero, Surco, Lima, Peru and on second call, on March 31, 2026, at the same time and place, for the purpose of submitting for consideration of the Meeting the following matters: Statement on Social Management and economic results (integrated annual report, external audit report and financial statements for fiscal year 2025). Ratification of the d

    2/13/26 7:17:00 AM ET
    $CPAC
    Building Materials
    Industrials

    Annaly Capital Management, Inc. Announces Retirement of Chief Legal Officer

    Annaly Capital Management, Inc. (NYSE:NLY) ("Annaly" or the "Company") announced today that Anthony Green, the Chief Legal Officer, Chief Corporate Officer and Secretary and a senior member of the executive team, will be retiring after a distinguished 16 years with Annaly. Effective January 1, 2026, Mr. Green will become a Senior Advisor to the Company through March 31, 2026. Since joining the Company in 2009, Mr. Green has been pivotal in his multiple roles within the legal department, culminating in his appointment as the Chief Legal Officer in 2017 and the Chief Corporate Officer in 2019, where he was responsible for the Company's legal and compliance groups, corporate responsibility e

    12/29/25 4:15:00 PM ET
    $NLY
    Real Estate Investment Trusts
    Real Estate

    $ALBO
    $AMGN
    $ARBE
    $BAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Annaly Capital Management Inc.

    SC 13G - ANNALY CAPITAL MANAGEMENT INC (0001043219) (Subject)

    11/14/24 1:22:37 PM ET
    $NLY
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by e.l.f. Beauty Inc.

    SC 13G/A - e.l.f. Beauty, Inc. (0001600033) (Subject)

    11/12/24 2:20:13 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by e.l.f. Beauty Inc.

    SC 13G/A - e.l.f. Beauty, Inc. (0001600033) (Subject)

    11/4/24 11:47:14 AM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary